共 50 条
- [1] Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A[J]. EUROPEAN RESPIRATORY JOURNAL, 2021, 58Pilette, CharlesCanonica, Giorgio WalterChaudhuri, RekhaLee, F. Eun-HyungLee, Jason KihyukAlmonacid Sanchez, CarlosAlfonso-Cristancho, RafaelJakes, RupertMaxwell, AoifePrice, RobertHowarth, Peter
- [2] Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis[J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (04)Harrison, TimCanonica, Giorgio WalterChupp, GeoffreyLee, JasonSchleich, FlorenceWelte, TobiasValero, AntonioGemzoe, KimMaxwell, AoifeJoksaite, SandraYang, ShibingHowarth, PeterVan Dyke, Melissa K.
- [3] International, prospective study of mepolizumab in severe asthma: REALITI-A at 2yrs[J]. EUROPEAN RESPIRATORY JOURNAL, 2022, 60Caruso, C.Canonica, G. W.Patel, M.Smith, A.Liu, M. C.Alfonso-Cristancho, R.Price, R. G.Jakes, R. W.Demetriou, L.Valero, A.Pilette, C.Howarth, P.
- [4] REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (10): : 2646 - 2656Pilette, CharlesCanonica, Giorgio WalterChaudhuri, RekhaChupp, GeoffreyLee, F. Eun-HyungLee, Jason KihyukAlmonacid, CarlosWelte, TobiasAlfonso-Cristancho, RafaelJakes, Rupert W.Maxwell, AoifePrice, Robert G.Howarth, Peter
- [5] Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB20 - AB20Chupp, GeoffreyHeaney, LiamPrice, RobBrusselle, GuyGardiner, FrancesRaimondi, AlejandroChaudhuri, RekhaHowarth, Peter
- [6] National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study[J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205Lee, J. K.Schleich, F.Canonica, G. W.Munoz, X.Chaudhuri, R.Lee, F. E.Howarth, P.Price, R. G.Yang, S.Jakes, R. W.Maxwell, A.Cristancho, R. Alfonso
- [7] Characteristics of patients receiving mepolizumab in real-world practice - REALITI-A study[J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52Kwon, NamheeGemzoe, KimWorsley, SallyGunsoy, NecdetJoksaite, SandraVan Dyke, MelissaBettinson, CarysAlbers, Frank
- [8] Real-world outcomes with mepolizumab in patients with severe asthma and comorbid anxiety/depression: REALITI-A at 2 years[J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62Chaudhuri, RekhaLiu, Mark C.Bagnasco, DiegoMatucci, AndreaPilette, CharlesPrice, Robert G.Demetriou, LydiaHowarth, Peter
- [9] Real-world mepolizumab outcomes in severe asthma: REALITI-A post hoc analysis by exacerbation history[J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 62Bagnasco, DiegoLougheed, DianeSubramanian, VijayClifton, Ian J.Price, Robert G.Howarth, Peter
- [10] The impact of comorbid nasal polyps on real-world mepolizumab effectiveness in patients with severe asthma: Results from the REALITI-A study[J]. ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 566 - 566Liu, Mark C.Bagnasco, DiegoMatucci, AndreaPilette, CharlesPrice, Robert G.Maxwell, Aoife C.Alfonso-Cristancho, RafaelJakes, Rupert W.Yang, ShibingHowarth, PeterCheema, Amarjit S.